KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti-PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC)

被引：0
|
作者：
Lai, W. C. V. [1 ]
Ahn, M-J. [2 ]
Shentzer, T. [3 ]
Kowalski, D. [4 ]
Cho, B. C. [5 ]
Schmid, S. [6 ]
Jove, M. [7 ]
Huang, M. [8 ]
Zhao, B. [8 ]
El-Osta, H. [8 ]
Navarro, A. [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] Rambam Med Ctr, Dept Med Oncol, Haifa, Israel
[4] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Med Oncol, Warsaw, Poland
[5] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[6] Kantonsspital St Gallen, Dept Med Oncol, St Gallen, Switzerland
[7] Inst Catala Oncol, Barcelona, Spain
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.134
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
116TiP
引用
收藏
页码：S1425 / S1426
页数：2
相关论文
共 50 条
  • [31] Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.
    Cheng, Ying
    Han, Liang
    Wu, Lin
    Chen, Jun
    Sun, Hongmei
    Wen, Guilan
    Ji, Yinghua
    Dvorkin, Mikhail
    Shi, Jianhua
    Pan, Zhijie
    Shi, Jinsheng
    Wang, Xicheng
    Bai, Yuansong
    Melkadze, Tamar
    Pan, Yueyin
    Min, Xuhong
    Viguro, Maksym
    Xu, Yan
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): The results from a phase II single-arm study.
    Fan, Yun
    Wang, Zhehai
    Yang, Runxiang
    Min, Xuhong
    Ma, Huiwen
    Wang, Yan
    Chen, Zhendong
    Wang, Hongmin
    Wang, Huayuan
    Fang, Lianghua
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin plus etoposide plus nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study
    Kalinka, E.
    Bahce, I.
    Navarro Mendivil, A. F.
    Ready, N.
    Chu, Q. S-C.
    Sugawara, S.
    Sibille, A.
    Provencio Pulla, M.
    Johnson, M. L.
    Hiltermann, J. T. J. N.
    Ciuleanu, T-E.
    Dziadziuszko, R.
    Santo, A.
    Zhang, Y.
    Liu, Y.
    Sarmiento, R.
    Tannenbaum-Dvir, S.
    Ojalvo, L.
    Wu, J.
    O'Byrne, K. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1061 - S1062
  • [34] Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study
    Thomas, M.
    Ponce Aix, S.
    Navarro Mendivil, A.
    Riera Knorrenschild, J.
    Schmidt, M.
    Wiegert, E.
    Kapp, K.
    Mauri, C.
    Domine Gomez, M.
    Kollmeier, J.
    Sadjadian, P.
    Froehling, K-P.
    Huber, R. M.
    Wolf, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 599 - 599
  • [35] Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer
    Yu, Hui
    Chen, Ping
    Cai, Xiuyu
    Chen, Chen
    Zhang, Xuanye
    He, Lina
    Zhou, Yixin
    Hong, Shaodong
    Zhang, Bei
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (03) : 637 - 644
  • [36] Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer
    Hui Yu
    Ping Chen
    Xiuyu Cai
    Chen Chen
    Xuanye Zhang
    Lina He
    Yixin Zhou
    Shaodong Hong
    Bei Zhang
    Cancer Immunology, Immunotherapy, 2022, 71 : 637 - 644
  • [37] Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer
    Shaw, Jaime
    Pundole, Xerxes
    Balasubramanian, Akhila
    Anderson, Erik S.
    Pastel, Malaika
    Bebb, D. Gwyn
    Jiang, Tony
    Martinez, Pablo
    Ramalingam, Suresh S.
    Borghaei, Hossein
    ONCOLOGIST, 2024, 29 (12): : 1079 - 1089
  • [38] THE COST EFFECTIVENESS ANALYSIS OF PD-1 AND PD-L1 AGENTS COMPARED WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Bae-Shaaw, Y. H.
    Hay, J. W.
    VALUE IN HEALTH, 2018, 21 : S30 - S30
  • [39] A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer
    Chen, Can
    Chen, Minjun
    Bai, Yuju
    Li, Yajun
    Peng, Jie
    Yao, Biao
    Feng, Jiangping
    Zhou, Jian-Guo
    Ma, Hu
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [40] An open-label, multicenter, phase Ib/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC).
    Yu, Yongfeng
    Huang, Dingzhi
    Pan, Hongming
    Li, Chun-lai
    Wang, Sheng
    Guo, Hai-jun
    Su, Rong
    Zhang, Li-qin
    Li, Shi-chang
    Wang, Yi-wei
    Hei, Yong-Jiang
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345